<p>Poteligeo is a cancer medicine used to treat mycosis fungoides and Sezary syndrome – two cancers of blood cells that affect mainly the skin. It is used in patients who have received previous treatment by mouth or injection.</p><p>Both mycosis fungoides and Sezary syndrome belong to a group of rare cancers (cutaneous T-cell lymphomas), and Poteligeo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 14 October 2016. Further information on the orphan designation can be found here: <a href="/en/medicines/human/orphan-designations/eu-3-16-1756" data-entity-type="node" data-entity-uuid="55211c3d-bf0b-49aa-95f4-cc4e23a8a3e3" data-entity-substitution="canonical">ema.europa.eu/Find medicine/Human medicines/Rare disease designation</a></p><p>Poteligeo contains the active substance mogamulizumab.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p style="margin-left:5.4pt;">Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.</p> </div>
Therapeutic Area (MeSH)
ATC Code
L01XC25
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| mogamulizumab | N/A | mogamulizumab |
EMA Name
Poteligeo
Medicine Name
Poteligeo
Aliases
N/ANo risk management plan link.
